Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT.
Soepenberg O, et al.
Clin Cancer Res. 2005 Feb 15;11(4):1504-11. doi: 10.1158/1078-0432.CCR-04-1758.
Clin Cancer Res. 2005.
PMID: 15746053
Free article.
Clinical Trial.